Sign in to view content

Board-Certified Providers Are Associated With a Reduced Risk of Endophthalmitis After Intravitreal Injections

Geoffrey G. Emerson, MD, PhD, FASRS

Video
Published 2021

Related

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Endophthalmitis Rates of Prefilled Ranibizumab Syringes Compared to Conventional Ranibizumab Vials: An International Multicenter Study
Yoshihiro Yonekawa, MD, FASRS
Annual Meeting Talks
2018
Genetic Testing to Identify Ocular Pathogens in Endophthalmitis and Uveitis
Harpal A.S. Sandhu, MD, FRCSC
On Demand Cases, Courses, and Papers
2017

Category: Socioeconomics

See more